Genetics in Medicine 2012-01-01

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

Yoav H Messinger, Nancy J Mendelsohn, William Rhead, David Dimmock, Eli Hershkovitz, Michael Champion, Simon A Jones, Rebecca Olson, Amy White, Cara Wells, Deeksha Bali, Laura E Case, Sarah P Young, Amy S Rosenberg, Priya S Kishnani

Index: Genet. Med. 14(1) , 135-42, (2012)

Full Text: HTML

Abstract

Infantile Pompe disease resulting from a deficiency of lysosomal acid α-glucosidase (GAA) requires enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly. We describe successful tolerance induction in CRIM-negative patients.Two CRIM-negative patients with preexisting anti-GAA antibodies were treated therapeutically with rituximab, methotrexate, and gammaglobulins. Two additional CRIM-negative patients were treated prophylactically with a short course of rituximab and methotrexate, in parallel with initiating rhGAA.In both patients treated therapeutically, anti-rhGAA was eliminated after 3 and 19 months. All four patients are immune tolerant to rhGAA, off immune therapy, showing B-cell recovery while continuing to receive ERT at ages 36 and 56 months (therapeutic) and 18 and 35 months (prophylactic). All patients show clinical response to ERT, in stark contrast to the rapid deterioration of their nontolerized CRIM-negative counterparts.The combination of rituximab with methotrexate ± intravenous gammaglobulins (IVIG) is an option for tolerance induction of CRIM-negative Pompe to ERT when instituted in the naïve setting or following antibody development. It should be considered in other conditions in which antibody response to the therapeutic protein elicits robust antibody response that interferes with product efficacy.


Related Compounds

Related Articles:

Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.

1990-07-01

[Clin. Chem. 36(7) , 1381, (1990)]

Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.

2009-07-01

[Genet. Med. 11 , 536-541, (2009)]

Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.

2012-02-15

[Am. J. Med. Genet. C. Semin. Med. Genet. 160 , 50-58, (2012)]

Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.

2000-12-01

[Anal. Biochem. 287 , 136-143, (2000)]

Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases.

2012-03-01

[J. Inherit. Metab. Dis. 35(2) , 311-6, (2011)]

More Articles...